4Jarvis WR . Epidemiology of nosocomial fungal infections, with emphasis on Candida species. Clin Infect Dis, 1995,20:1526-1530.
5Kao AS, Brandt ME, Pruitt WR, et al. The epidemiology of candidemia in two United States cities: results of a population-based active surveillance. Clin Infect Dis, 1999,29:1164-1170.
6Verduyn Lunel FM, Meis JF, Voss A, et al. Nosocomial fungal infections:candidemia. Diagn Microbiol Infect Dis, 1999,34:213-220.
7Edmond MB, Wallace SE, McClish DK,et al. Nosocomial bloodstream infections in United States hospitals: a three-year analysis. Clin Infect Dis, 1999,29: 239-244.
8Beck-Sague C, Jarvis WR. Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-1990.National Nosocomail Infections Surveillance System . J Infect Dis, 1993, 167:1247-1251.
9Haddad NE, Powderly WG. The changing face of mycoses in patients with HIV/AIDS. AIDS Read, 2001,11: 375-378.
10Rex JH, Bennett JE, Sugar AM, et al. Intravascular catheter exchange and duration of candidemia. NIAID Mycoses Study Group and the Candidemia Study Group. Clin Infect Dis, 1995,21:994-996.
2Michael C,Teichert J ,Preiss R in human plasma and saliva Determination of voriconazole using high-performance liquid chromatography with fluorescence detection[J]. J Chroma togr B Analyt Technol Life Sci,2008,865(1-2) :74-80.
3Mizutani T. PM frequencies of major CYPs in Asians and Caucasians[J]. Drug Metab Rev,2003,35(2-3) :99-106.
4Smith J,Safdar N, Knasinski V, et al. Vorieonazole therapeutic drug monitoring[J]. Antimicrob Agents Chemother,2006, 50(4) : 1570-1572.
5Pascual A,Calandra T,Bolay S, et al. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes[J]. Clin Infect Dis,2008, 46(2) ,201-211.
